Cargando…

Biotin Interference in Point of Care HIV Immunoassay

The use of high concentrations of biotin as a dietary supplement to improve hair, skin, and nail quality has increased in the United States over the past few years. High concentrations of biotin have been shown to interfere with some diagnostic assays that use streptavidin–biotin interactions as one...

Descripción completa

Detalles Bibliográficos
Autores principales: Haleyur Giri Setty, Mohan Kumar, Lee, Sherwin, Lathrop, Julia, Hewlett, Indira K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703309/
https://www.ncbi.nlm.nih.gov/pubmed/33269113
http://dx.doi.org/10.1089/biores.2020.0038
_version_ 1783616623192571904
author Haleyur Giri Setty, Mohan Kumar
Lee, Sherwin
Lathrop, Julia
Hewlett, Indira K.
author_facet Haleyur Giri Setty, Mohan Kumar
Lee, Sherwin
Lathrop, Julia
Hewlett, Indira K.
author_sort Haleyur Giri Setty, Mohan Kumar
collection PubMed
description The use of high concentrations of biotin as a dietary supplement to improve hair, skin, and nail quality has increased in the United States over the past few years. High concentrations of biotin have been shown to interfere with some diagnostic assays that use streptavidin–biotin interactions as one of the steps in the assay. The objective of this report is to evaluate potential biotin interference on the analytical and clinical sensitivity of a point of care (POC) antigen–antibody combo HIV-1 assay. We spiked biotin at concentrations ranging from 12.5 to 400 ng/mL into serum and plasma containing HIV-1 subtype B p24 antigen derived from culture supernatant. The p24 antigen was present in the matrices at 30 pg/mL. Fifty microliters of each sample was applied to Alere Determine HIV-1/2 Ag/Ab combo assay strips in duplicate and results were read by eye after 20 to 30 min. Biotin interfered with detection of HIV-1 p24 in serum and plasma. HIV-1 p24 was not detected at 30 pg/mL p24 when biotin was present at 200 ng/mL concentration. Our study demonstrated that elevated levels of biotin in samples may interfere with POC assays. It is important to consider biotin supplements as potential sources of falsely increased or decreased test results, especially in cases wherein supplementation cannot be ruled out.
format Online
Article
Text
id pubmed-7703309
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-77033092020-12-01 Biotin Interference in Point of Care HIV Immunoassay Haleyur Giri Setty, Mohan Kumar Lee, Sherwin Lathrop, Julia Hewlett, Indira K. Biores Open Access Original Research Article The use of high concentrations of biotin as a dietary supplement to improve hair, skin, and nail quality has increased in the United States over the past few years. High concentrations of biotin have been shown to interfere with some diagnostic assays that use streptavidin–biotin interactions as one of the steps in the assay. The objective of this report is to evaluate potential biotin interference on the analytical and clinical sensitivity of a point of care (POC) antigen–antibody combo HIV-1 assay. We spiked biotin at concentrations ranging from 12.5 to 400 ng/mL into serum and plasma containing HIV-1 subtype B p24 antigen derived from culture supernatant. The p24 antigen was present in the matrices at 30 pg/mL. Fifty microliters of each sample was applied to Alere Determine HIV-1/2 Ag/Ab combo assay strips in duplicate and results were read by eye after 20 to 30 min. Biotin interfered with detection of HIV-1 p24 in serum and plasma. HIV-1 p24 was not detected at 30 pg/mL p24 when biotin was present at 200 ng/mL concentration. Our study demonstrated that elevated levels of biotin in samples may interfere with POC assays. It is important to consider biotin supplements as potential sources of falsely increased or decreased test results, especially in cases wherein supplementation cannot be ruled out. Mary Ann Liebert, Inc., publishers 2020-11-24 /pmc/articles/PMC7703309/ /pubmed/33269113 http://dx.doi.org/10.1089/biores.2020.0038 Text en © Mohan Kumar Haleyur Giri Setty et al., 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Haleyur Giri Setty, Mohan Kumar
Lee, Sherwin
Lathrop, Julia
Hewlett, Indira K.
Biotin Interference in Point of Care HIV Immunoassay
title Biotin Interference in Point of Care HIV Immunoassay
title_full Biotin Interference in Point of Care HIV Immunoassay
title_fullStr Biotin Interference in Point of Care HIV Immunoassay
title_full_unstemmed Biotin Interference in Point of Care HIV Immunoassay
title_short Biotin Interference in Point of Care HIV Immunoassay
title_sort biotin interference in point of care hiv immunoassay
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703309/
https://www.ncbi.nlm.nih.gov/pubmed/33269113
http://dx.doi.org/10.1089/biores.2020.0038
work_keys_str_mv AT haleyurgirisettymohankumar biotininterferenceinpointofcarehivimmunoassay
AT leesherwin biotininterferenceinpointofcarehivimmunoassay
AT lathropjulia biotininterferenceinpointofcarehivimmunoassay
AT hewlettindirak biotininterferenceinpointofcarehivimmunoassay